pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
165
stories
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
Eli Lilly issues data sharing ultimatum to 340B hospitals
biopharma dive
Jun 1, 26
CDC says containing the spread of Ebola is top priority
stat
Jun 1, 26
STAT+: Medicare still won’t say how much covering obesity drugs will cost
stat
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 19, 26
Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
endpoints
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 11, 26
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
endpoints
May 11, 26
New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
endpoints
May 11, 26
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
stat
May 8, 26
STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
stat
May 8, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 8, 26
STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
stat
May 7, 26
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
stat
May 7, 26
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
stat
May 7, 26
STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
stat
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 7, 26
STAT+: Next-gen Duchenne drug from Entrada disappoints
stat
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 6, 26
STAT+: Oregon hospitals won’t outsource to national physician chain after all
stat
May 6, 26
STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
stat
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
← prev
page 5 of 6
next →
